Navigation Links
Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Date:11/2/2010

BASKING RIDGE, N.J., Nov. 2, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, presented an abstract at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions on November 2, 2010 in Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition of Factor IXa by Subcutaneous RB006 with Active Reversal: First-in-Human Experience with the REG2 System."

The REG2 system is intended for use in venous thrombosis indications.  This initial Phase 1 study was the first successful subcutaneous application of an aptamer in humans.  It demonstrated that a single subcutaneous injection of RB006 (aka pegnivacogin) resulted in dose-dependent inhibition of Factor IXa with effects that persisted longer than one week after injection. The data is promising for future development of REG2.

The abstract is coauthored by Steven L. Zelenkofske, D.O., Christopher P. Rusconi, Ph.D. and Carolyn M. Darmiento, MS, all from Regado Biosciences; and Richard C. Becker, MD, Duke University School of Medicine, Durham, NC and William Wargin, Ph.D., President of PK-PM Associates, LLC.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015  Only a quarter of ... managing the patients they prescribe them to, according to ... School of Medicine (BUSM) and myCME , ... Daniel Alford, M.D. , director of BUSM,s ... program , said, "This indicates a critical need for ...
(Date:6/2/2015)... -- ErgoNurse, the leader in bedside safety management solutions, and Briggs ... the United States , have formalized a partnership to ... nursing markets. ... Thousands of healthcare professionals in acute ... the ErgoNurse products to stop unnecessarily utilizing their backs for ...
(Date:6/2/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research ... it has reached an agreement to settle the stockholder ... Court of Chancery, which names as defendants a ... officers, and names the Company as a nominal defendant. ... Corp. Stockholder Derivative Litigation , C.A. No. 9864-VCL, relates ...
Breaking Medicine Technology:Survey Results Show Few Doctors Are Very Confident Managing Patients on Opioids 2ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4
... Vaginal Supplement Studied in Largest-Ever IVF Trial,in ... /PRNewswire/ -- Results of,four studies evaluating Ferring ... development for luteal phase,support (supplementation to provide ... pregnancy) in assisted reproductive,technologies (ART) were presented ...
... April 18, 2007,/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today ... a functional,biomarker for its novel histone deacetylase ... with its,Bruton's tyrosine kinase (BTK) inhibitor compounds. ... for Cancer Research (AACR),2007 Annual Meeting being ...
Cached Medicine Technology:Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 2Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 3Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 4Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 5Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5
(Date:6/2/2015)... Detroit, MI (PRWEB) June 02, 2015 ... called “Fighting Addiction Together” in the Hall of Legends ... wide receiver and motivational speaker Herman Moore, the goal ... state of addiction in today’s society, highlight the benefits ... to inform the attendees about the options that are ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Residents looking ... quality care in a more convenient location now that ... Partin Village Plaza, 2310 E. Irlo Bronson Memorial Highway, ... located less than a mile away from its original ... décor, more spacious patient areas with digital intraoral and ...
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations and ... urgent care services in Los Angeles County. The ... California Board of Regents and the Exer Board of ... purchase a minority share of four existing Exer urgent ... Northridge and creates opportunity to grow and develop new, ...
(Date:6/2/2015)... June 02, 2015 The nation’s ... lawsuit ( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) is now underway in ... court documents, opening statements were presented on May ... etchings on the Profemur hip replacement made the ... to snap just three years after it had ...
(Date:6/2/2015)... Radaris ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, and Windows. ... the app review and shared with viewers can help users ... According to Psychology Today, humans are a curious species by ... is a part of human development. People are using the ...
Breaking Medicine News(10 mins):Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2Health News:Coast Dental Office Opening In Kissimmee with Expanded Technology 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 3Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2
... , Girling Health Care to utilize Santrax Time and ... , PORT WASHINGTON, N.Y. and AUSTIN, Texas, June ... of information technology solutions to the home healthcare and ... Healthcare company, announced an agreement by which Girling will ...
... Va., June 23 According to a new report from ... screened by doctors for depression. The group said that all ... show potential risk for depression and suicidal tendencies. While there ... of kids, the mental and emotional health of children does ...
... "Deinstallation" Seen Among Physician Groups in Phoenix ... , NASHVILLE, Tenn., June ... intelligence, reports that while health systems and physician groups in ... in adopting electronic medical records (EMR), there is a high ...
... Region recognizes ... ... Medical Center and CHRISTUS St. Vincent Medical Group in Santa Fe, New Mexico, through teamwork, ... in nine months. CHRISTUS Health began managing CHRISTUS St. Vincent in April 2008 ...
... is Nordic Naturals newest product for children, the "ultimate fish ... natural tangerine flavor. Perfect for two-year-olds and up, Nordic Omega-3 ... from anchovies and sardines, two sustainable sources of high quality ... mg of fish oil and offers 136 mg of omega-3. ...
... ... Work Harder for Them to Achieve Better ROI , ... Scottsdale, Ariz. (PRWEB) June 23, 2009 -- In ... leaving enterprises vulnerable to threats. According to the Ponemon Institute, 2008 Cost of a ...
Cached Medicine News:Health News:Harden Healthcare Expands Relationship with Sandata Technologies 2Health News:Should All Kids Be Screened for Depression? This Expert Says Yes and Explains How It Can Save Lives 2Health News:Electronic Medical Record Technology Uptake Faces Challenges 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 2Health News:CHRISTUS Health New Mexico Region Focuses on Cost Management; Saves $1.8 Million 3Health News:Nordic Omega-3 Fishies from Nordic Naturals Offers Quality EPA and DHA for Children with 'Kid Pleasin' Taste 2Health News:Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 2Health News:Lumension Audiocast With Aberdeen Group Highlights How to Reduce IT Costs By Effectively Managing and Securing Endpoints 3
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
... four-color, automated benchtop flow cytometry system that ... Designed specifically to support a wide range ... instrument control, auto-sample loading, and push-button fluidic ... is fully modular so it can be ...
... cytometer especially suited for cell analysis ... CyFlow allows to analyze scatter signals ... fluorescence channels. Data acquisition, analysis, and ... built-in PC employing Partec DPAC software, ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: